Shanghai Xiao Fang PharmaceuticalLtd Past Earnings Performance
Past criteria checks 4/6
Shanghai Xiao Fang PharmaceuticalLtd has been growing earnings at an average annual rate of 9%, while the Pharmaceuticals industry saw earnings growing at 9% annually. Revenues have been growing at an average rate of 2% per year. Shanghai Xiao Fang PharmaceuticalLtd's return on equity is 29.2%, and it has net margins of 43.2%.
Key information
9.0%
Earnings growth rate
8.3%
EPS growth rate
| Pharmaceuticals Industry Growth | 10.9% |
| Revenue growth rate | 2.0% |
| Return on equity | 29.2% |
| Net Margin | 43.2% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses Breakdown
How Shanghai Xiao Fang PharmaceuticalLtd makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 474 | 204 | 61 | 18 |
| 31 Mar 24 | 473 | 204 | 60 | 17 |
| 31 Dec 23 | 472 | 204 | 59 | 16 |
| 31 Dec 22 | 457 | 175 | 56 | 14 |
| 31 Dec 21 | 402 | 126 | 94 | 14 |
| 31 Dec 20 | 361 | 160 | 40 | 11 |
| 31 Dec 19 | 340 | 142 | 47 | 11 |
Quality Earnings: 603207 has a high level of non-cash earnings.
Growing Profit Margin: 603207's current net profit margins (43.2%) are higher than last year (40.8%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 603207's earnings have grown by 9% per year over the past 5 years.
Accelerating Growth: 603207's earnings growth over the past year (8%) is below its 5-year average (9% per year).
Earnings vs Industry: 603207 earnings growth over the past year (8%) exceeded the Pharmaceuticals industry -0.2%.
Return on Equity
High ROE: 603207's Return on Equity (29.2%) is considered high.